ClinicalTrials.gg
RecruitingNCT07102147Updated May 28, 2026

Telehealth Collaborative Care Model (CoCM) in Lung Cancer

An interventional study of High Touch Outreach in Lung Cancer (Diagnosis), Anxiety and Depression in Adults, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine — 2 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Abramson Cancer Center at Penn Medicine.

Planned enrollment
16th of 20
30 · median 55
Started
2025
with 2 others
No phase
12 of 26
2 open now
Registered
26th of 26
by date

Among the 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2025, is one of 12 with no phase, and was the 26th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

2 of the 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

The goal of this trial is to compare the impact of two outreach strategies (high touch vs. standard outreach) on a collaborative care program delivered via telehealth to patients with lung cancer.

Read the detailed description

The goal of this project is to pilot test the effectiveness of using a more-intensive (high touch) outreach strategy to increase the reach of an adapted, standard of care CoCM for patients with lung cancer who are experiencing depression and/or anxiety. The investigators will specifically test the effect of two outreach strategies (high touch vs. standard outreach) on reach of the CoCM program (primary outcome) and on several secondary implementation and effectiveness outcomes. Given the demonstrated efficacy of the CoCM in patients with cancer, the main target of this research study is the impact of the outreach strategies and delivery of the CoCM via telehealth.

03

Conditions studied

  • Lung Cancer (Diagnosis)
  • Anxiety
  • Depression in Adults

Keywords

  • Lung cancer
  • Anxiety
  • Depression
  • Collaborative care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are aged 18 years or older.
  • Are currently being seen by Penn Medicine Thoracic Oncology for lung cancer treatment or survivorship care.
  • Are referred to collaborative care by a Penn Medicine Thoracic Oncology clinician for treatment of depression, anxiety, or other psycho-therapy services.

Exclusion criteria

Exclusion Criteria:

  • Are already receiving psycho-therapy treatment services outside of Penn Medicine's collaborative care program, Penn Integrated Care (PIC).
  • Have a significant and/or untreated medical and/or psychiatric co-morbidity (e.g., other cancers, schizophrenia, acute suicidal and/or homicidal ideation) that make them ineligible for the Penn CoCM program.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High Touch Outreach

    Patients in the high touch outreach arm will receive a gain-framed message via text (preferred modality), MyPennMedicine message, email, and/or postal mail that links to the digital screener; an informational flyer about collaborative care sent via postal mail, the MyPennMedicine portal, email, and/or text; and a direct request from their oncology provider to collaborative care for those patients who have not responded to outreach efforts by their next oncology visit post-referral.

    Behavioral: High Touch Outreach

  • No intervention
    Standard Outreach

    Patients in the standard outreach arm will receive a standard message sent via text (preferred modality), MyPennMedicine message, email, and/or postal mail that links to the digital screener; this message is one that is similar to that already used in Penn Integrated Care's practice.

Interventions

  • BehavioralHigh Touch Outreach

    Gain-framed message, informational flyer, and direct request

06

What researchers measure

Primary outcomes

  1. Reach - Completion of the intake assessment amongst referred patients.

    The number of referred patients that complete the intake assessment divided by the total number of referred patients.

    Time frame: Measured per patient up to 30 days after randomization.

Secondary outcomes

  1. Treatment Initiation - Completion of one or more oncology-based collaborative care appointments amongst patients deemed to be appropriate for oncology-based collaborative care at intake.

    The number of patients deemed to be appropriate for the oncology-based CoCM at intake who go on to complete one or more oncology-based CoCM appointments divided by the total number of patients deemed to be appropriate for the oncology-based CoCM at intake.

    Time frame: Measured per patient up to 60 days after randomization.

  2. Treatment Retention - Completion of oncology-based collaborative care appointments amongst patients deemed to be appropriate for oncology-based collaborative care at intake.

    Number of oncology-based collaborative care appointments completed amongst patients deemed to be appropriate for the oncology-based CoCM at intake.

    Time frame: Measured per patient at end of collaborative care treatment (assessed up to 6 months).

  3. Clinical Effectiveness (PHQ-9) - Change in symptom measure using the Patient Health Questionnaire-9 (PHQ-9) validated instrument.

    The change in PHQ-9 score from the patient's collaborative care intake appointment to the appointment most proximal to the patient's discharge. The instrument's minimum value is 0 and maximum value is 27, with a higher score indicating a worse outcome.

    Time frame: Measured per patient at first collaborative care appointment (baseline) and at end of collaborative care treatment (up to 6 months).

  4. Clinical Effectiveness (GAD-7) - Change in symptom measure using the Generalized Anxiety Disorder-7 item (GAD-7) validated instrument.

    The change in GAD-7 score from the patient's collaborative care intake appointment to the appointment most proximal to the patient's discharge. The instrument's minimum value is 0 and maximum value is 21, with a higher score indicating a worse outcome.

    Time frame: Measured per patient at first collaborative care appointment (baseline) and at end of collaborative care treatment (up to 6 months).

  5. Clinical Effectiveness (PROMIS Fatigue) - Change in symptom measure using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue - Short Form 7a validated instrument.

    The change in PROMIS Fatigue - Short Form 7a score from the patient's collaborative care intake appointment to the appointment most proximal to the patient's discharge. The instrument's minimum value is 7 and maximum value is 35, with a higher score indicating a worse outcome.

    Time frame: Measured per patient at first collaborative care appointment (baseline) and at end of collaborative care treatment (up to 6 months).

07

Study locations

1 of 1 sites recruiting
  • Abramson Cancer Center at the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Alexandria Muench, PsyD · Contactamuench@pennmedicine.upenn.edu · 215-421-4491
    • Courtney Wolk, PhD · Sub investigator
    • Matthew Press, MD, MSc · Sub investigator
    • Aditi Singh, MD · Sub investigator
    • Faith Mutale, CRNP · Sub investigator
    • Katharine Rendle, PhD, MSW · Sub investigator
    • Anil Vachani, MD, MS · Sub investigator
    • Kristin Linn, PhD · Sub investigator
    • Eleanor Anderson, MD · Sub investigator
    • Tiffany Hogan, MA, CCC-SLP · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 19 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 3, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07102147
Responsible party
Alexandria Muench (Staff Psychologist, Abramson Cancer Center at Penn Medicine) — Principal investigator
First posted
Aug 3, 2025
Start date
Aug 18, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 28, 2026

Study contacts

Jennifer Steltz, MRA
Contact
jennifer.steltz@pennmedicine.upenn.edu
215-573-2593
Jocelyn Wainwright, MS
Contact
jocelyn.wainwright@pennmedicine.upenn.edu
215-615-4226
Alexandria Muench, PsyD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion